Response to: 'Correspondence on 'Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef et al ' by Lo et al

TY - JOUR

T1 - Response to

T2 - 'Correspondence on 'Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef et al ' by Lo et al

AU - Duarte-García, Ali

AU - Graef, Elizabeth R.

AU - Liew, Jean W.

AU - Konig, Maximilian F.

AU - Kim, Alfred Hyoungju

AU - Sparks, Jeffrey A.

N1 - Funding Information: Competing interests JWL reports grant funding from Pfizer, unrelated to this manuscript. MFK was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) under award no. T32AR048522 and received personal fees from Bristol-Myers Squibb and Celltrion, unrelated to this manuscript. AHK reports grants from Rheumatology Research Foundation, support from NIH/NIAMS, and personal fees from Exagen Diagnostics, and GlaxoSmithKline. JAS reports grants from NIH/NIAID/ Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute, and the R Bruce and Joan M Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum.

PY - 2022/9/1

Y1 - 2022/9/1

UR - https://www.scopus.com/pages/publications/85089980139

U2 - 10.1136/annrheumdis-2020-218680

DO - 10.1136/annrheumdis-2020-218680

M3 - Letter

C2 - 32769149

AN - SCOPUS:85089980139

SN - 0003-4967

VL - 81

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 9

M1 - e164

ER -